SCHEMBL9922340

SCHEMBL9922340

CS(=O)(=O)c1ccc2ccn(-c3ccc(NC(=O)NS(=O)(=O)c4ccc(Cl)s4)cc3Cl)c(=O)c2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RY12 Q9H244 5/20 0.43
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
HPGD P15428 1/20 0.40
HSD17B10 Q99714 1/20 0.39
FBP1 P09467 1/20 0.37
MAPT P10636 4/20 0.36
KDM4E B2RXH2 2/20 0.35
RECQL P46063 1/20 0.35
DOT1L Q8TEK3 1/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
KCNA1 Q09470 3/20 0.35
KCNAB1 Q14722 3/20 0.35
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CA9 Q16790 1/20 0.34
HTT P42858 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9922636 0.92 P2RY12 (0.48) P2RY12MEN1KMT2ASMN1; SMN2HPGD
SCHEMBL9922515 0.92 P2RY12 (0.42) P2RY12MEN1KMT2ASMN1; SMN2HSD17B10
SCHEMBL9922522 0.90 P2RY12 (0.44) P2RY12MEN1KMT2ASMN1; SMN2FBP1
SCHEMBL9923159 0.89 P2RY12 (0.49) P2RY12MEN1KMT2ASMN1; SMN2HPGD
SCHEMBL9922517 0.88 P2RY12 (0.43) P2RY12MEN1KMT2ASMN1; SMN2FBP1
SCHEMBL9922523 0.88 P2RY12 (0.46) P2RY12MEN1KMT2ASMN1; SMN2FBP1
SCHEMBL9922333 0.88 P2RY12 (0.43) P2RY12MEN1KMT2ASMN1; SMN2FBP1
SCHEMBL9922341 0.88 P2RY12 (0.43) P2RY12MEN1KMT2ASMN1; SMN2HPGD
SCHEMBL9922720 0.87 P2RY12 (0.44) P2RY12MEN1KMT2ASMN1; SMN2FBP1
SCHEMBL9922516 0.87 P2RY12 (0.43) P2RY12MEN1KMT2ASMN1; SMN2FBP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8524721-B2 Platelet ADP receptor inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2013-09-03 US disclosed
US-20120149688-A1 PLATELET ADP RECEPTOR INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2012-06-14 US disclosed
US-8067428-B2 Platelet ADP receptor inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2011-11-29 US disclosed
US-20100234350-A1 PLATELET ADP RECEPTOR INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2010-09-16 US disclosed
US-7622474-B2 Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis PORTOLA PHARMACEUTICALS, INC. (US) 2009-11-24 US disclosed
US-7358257-B2 sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives; effective for prevention and treatment of cardiovascular diseases, antithrombotic agents PORTOLA PHARMACEUTICALS, INC. (US) 2008-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234350-A1 PLATELET ADP RECEPTOR INHIBITORS TBXA2R, GP6, P2RY6 P2RY12 19/4885MEN1 4498/4885KMT2A 3009/4885
US-20120149688-A1 PLATELET ADP RECEPTOR INHIBITORS TBXA2R, GP6, P2RY6 P2RY12 18/4885MEN1 4499/4885KMT2A 3023/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.